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Abstract
Remarkable progress in the experimental and clinical applications of cell-based therapies
has identified stem cells and their derived products as potential candidates for regenera‐
tive therapies for many disorders. The use of autologous stem cells as source for regener‐
ative therapeutic products is strongly limited by their low availability. Therefore, the
future applications of in vitro pharmed therapeutic cell products will most likely occur in
an allogeneic manner. However, the high variability of the human leukocyte antigen
(HLA) represents a major obstacle to the application of off-the-shelf products. We have
developed a strategy to decrease the immunogenicity of in vitro generated cell products
by silencing HLA expression using RNAi. HLA expression was permanently silenced in
CD34+ hematopoietic stem and progenitor cells and induced the pluripotent stem cells to
generate HLA-universal cells sources, which were then used for the differentiation of low
immunogenic cell products. In this chapter, we will provide an overview about an RNAi-
based strategy to reduce the immunogenicity of cell-based therapies, and in particular in
the generation of HLA-universal platelets and tissues.
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1. Introduction
The high variability of the human leukocyte antigen (HLA) constitutes a major hurdle in
allogeneic transplantation and to the application of off-the-shelf cell products in regenerative
medicine. Recently, remarkable progresses in the field of stem cell biology, cell pharming, and
tissue engineering have made feasible the differentiation of cells and tissues that might serve
as a bridging strategy or even an alternative to the very scarce donated tissues and organs.
However, HLA incompatibility may pose a threat to the applicability of such in vitro generated
cell products by increasing the risk of immune rejection after the transplantation.[1] To
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overcome this major hurdle in the fields of transplantation, cell and tissue engineering, we
have developed an RNA interference (RNAi)-based approach to reduce the immunogenicity
of cells and tissues, allowing their application in an universal manner. A lentiviral vector
encoding for specific short hairpins RNA (shRNA), targeting HLA transcripts were used to
achieve a permanent silencing of HLA expression. As HLA residual expression is crucial to
prevent the natural killer (NK) cell activity, RNAi appears as a superior tool in comparison to
gene editing technologies that cause a complete gene deletion such as the transcription
activator-like effector nuclease (TALEN) or clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas9 systems.[2-4] By decreasing the immunogenicity of cells and tissues,
the need for immunosuppressive regimens might be reduced after HLA-mismatched trans‐
plantation. Furthermore, as HLA plays a pivotal role in the recognition of virus-infected cells
and cancer cells, the combination of conditional promoter systems allows the re-expression of
HLA and constitutes a safety mechanism. The generation of low immunogenic cells and tissues
would bring enormous benefits to the patients and open novel horizons in the field of
transplantation and regenerative medicine.
2. The HLA system
Evolution conferred highly refined mechanisms to all animals from sponges to mammals to
distinguish self from non-self, and thereby allowing an immune response against potential
pathogens. In humans, a tight interplay between adaptive and innate immune systems allows
their defense against virtually all pathogens and cancer cells.[5, 6] Nevertheless, those
sophisticated surveillance mechanisms pose a major hurdle to allogeneic transplantation. The
alloimmune responses are mainly based on the recognition of mismatched major histocom‐
patibility complex (MHC) antigens by antibodies and T-cells. In humans, the MHC is known
as HLA and it comprises a group of linked genes. MHC class I and II regulate the immune
response through the presentation of peptides to T-cells. Allogeneic MHC in the graft’s
antigen-presenting cells (APCs) is recognized after transplantation through a direct pathway.
Afterwards, own patient APCs process and present the allogeneic antigens to T-cells by an
indirect alloantigen recognition pathway.[7, 8] HLA loci are encoded on the short arm of
human chromosome 6. Based on their structure, HLA molecules are grouped into class I and
class II (Figure 1). HLA class I classical genes comprise the A, B, and C loci, and are expressed
in the majority of cells. HLA class II genes include DR, DQ, and DP and are constitutively
expressed only in professional APCs.[9] The non-self recognition mediated by the engagement
of the T-cell receptor with the donor HLA is the basis for the allogeneic immune response.
2.1. HLA incompatibility increases the risk of rejection
Despite the progresses in the field of transplantation, graft rejection remains the major concern
regarding the application of off-the-shelf products. HLA comprises the most polymorphic loci
of the entire human genome. The probability to find a complete HLA-matched donor for a
specific patient is very low and, therefore, in most of the cases, patients will be treated with
partially HLA-mismatched tissues and organs. In addition, even in fully HLA donor/recipient
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pairs, disparities at the minor histocompatibility antigens (mHAg) derived from other
polymorphic proteins and presented at the HLA complexes are capable of triggering antigen-
specific immune responses that cause graft rejection. Improved use of post-transplant immu‐
nosuppression to prevent acute and chronic rejection allowed allogeneic transplantation as a
widespread, successful therapy.[10-13] However, graft rejection remains a major concern in
the field of transplantation. The registry of the International Society for Heart and Lung
Transplantation (ISHLT) reported that within the first year after lung transplantation, up to
55% patients need to be treated for acute rejection and only 50% are alive after five years.[14]
Also, the number of HLA mismatches between a donor/recipient pair is associated with
stronger immunosuppressive regimens. In particular, the number of HLA-DR mismatches and
the number of HLA-A and -B mismatches as well as rejection treatment showed significant
associations with the dose of maintenance steroids. Although immunosuppression allows the
acceptance of the allogeneic graft, it has severe side effects that may contribute to death even
with a functioning graft.[15] The occurrence of post-transplant complications related to the
immunosuppressive therapy such as cancer, opportunistic infection, toxicity, and hip fractures
have indicated the necessity to develop alternative strategies to allow the therapeutical use of
off-the-shelf HLA and mHAg-mismatched cell-based products.[16] Furthermore, due to the
shortage of organs and tissues for transplantation, there is a high demand regarding the
development of in vitro pharmed cell products, and engineered tissues or organs. Progresses
in the fields of stem cell biology and tissue engineering have demonstrated the feasibility to
generate in vitro potential alternative cell-based products that might serve as an alternative or
overcome the need for using donated tissues. Nevertheless, the future use of such products
will occur in an allogeneic manner, and therefore, it will be required that those products will
be able to escape an allogeneic immune response.
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Figure 1. Structure representation of (A) HLA class I (HLA-B) and (B) HLA class II (HLA-DQ) molecules. The struc‐
tures were designed using the software http://www.mh-hannover.de/institute/transfusion/histocheck/.
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2.2. RNAi-mediated HLA targeting as a strategy to decrease the cell immunogenicity
Rejection of allogeneic grafts is based on the recognition of the HLA complexes by the specific
pre-formed complement-binding anti-HLA antibodies or by the engagement of the T-cell
receptor, which leads to T-cell activation and the initiation of the immune response.[17, 18]
RNA interference is an invaluable technique in cell biology and regenerative strategies to
silence the target gene expression. Our studies have focused on the downregulation of HLA
class I and class II expression on the graft cells. So far, several strategies have been developed
to induce the acceptance of the allogeneic graft. Similar to the immunosuppression, those
strategies involve the modulation of immune responses and aim the induction of tolerance to
the graft. In our studies, we genetically modify the graft to silence its HLA expression to
prevent the recognition of the allogeneic graft as non-self by the recipient’s immune system.
In this approach, we do not induce tolerance toward the allogeneic graft, but we generate a
condition of immunological blindness in which the recipient’s immune system is not able to
recognize the allogeneic cells (due to the missing HLA) but is fully capable of defending the
patient against common clinical conditions associated with the use of immunosuppressive
drugs such as opportunistic infections and leukemia. To prevent the recognition of the grafted
cells as off the shelf, we have downregulated the expression of HLA class I and class II antigens
using RNAi. We have constructed lentiviral vectors encoding for short-hairpin RNA sequences
targeting β2-microglobulin (shβ2m) or the alpha-chain of HLA-DR (shDRA) to silence the
expression of HLA class I and class II antigens, respectively. Our studies demonstrated the
feasibility to stably downregulate HLA class I and II expression in several cell lines (e.g., B-
LCL, MonoMac-6, HeLa) as well as in primary cells (e.g., endothelial cells, CD34+ progenitor,
induced pluripotent stem cells). Cell transduction for the delivery of shRNAs targeting specific
HLA transcripts resulted in a decrease by up to 90% of β2m or HLA-DRA transcript levels and
HLA class I expression. In vitro assays have shown that HLA class I-silenced cells were
protected against the antibody-mediated complement-dependent cytotoxicity. Furthermore,
in T-cell cytotoxicity assays, significantly lower cell lysis rates were observed when HLA-
silenced cells were used as targets in comparison to fully HLA-expressing cells. In addition,
HLA-silenced cells demonstrated to induce significantly lower T-cell proliferation, pro-
inflammatory cytokine secretion, and degranulation. The residual HLA class I expression
showed to be sufficient to prevent NK cell cytotoxicity. Altogether, HLA-silenced cells showed
a protective effect against the humoral and cellular allogeneic immune response.[2, 3, 19]
2.3. MHC-silenced cells survive after fully HLA-incompatible transplantation
Despite the widespread use of immunosuppressive regimens to prevent graft rejection, their
therapeutic window is very narrow. Immunosuppressive drugs frequently cause adverse
effects including thrombocytopenia, leukopenia, hypercholesterolemia, stomatitis, nephro‐
toxicity, and diarrhea, and they lead to an increased risk for infections and cancer.[20, 21]
Silencing HLA expression using RNAi may represent an alternative to immunosuppression;
hence it has the potential to offer many benefits for the patients. In addition, silencing HLA
expression may allow the future application of HLA-mismatched off-the-shelf products in a
universal manner independently of the genetic background of the donor and recipient. In an
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allogeneic transplantation rat model, we have confirmed the improved capacity of MHC-
silenced cells to survive in allogeneic environment upon transplantation and even in the
absence of immunosuppression. A lentiviral vector encoding for a shRNA sequence targeting
rat MHC class I (RT1-A) and the sequence for firefly luciferase as a reporter gene was used to
silence MHC class I Lewis rat-derived fibroblasts. In contrast to nonmodified fibroblasts, MHC
class I-silenced fibroblasts were able to survive after subcutaneous transplantation in a
complete MHC-mismatched setting. MHC class I-silenced fibroblasts were able to engraft and
were detectable during the entire monitoring period (8 weeks). Nonmodified cells were
rejected in all animals.[22] This study showed the superior performance of MHC-silenced cells
after MHC-incompatible transplantation.
2.4. Generation of HLA-silenced platelets
Since the 1950s, blood transfusion therapy has become routine clinical practice; however, the
concept of blood pharming – ex vivo production of mature blood cells – is quite new. In
humans, platelet production is sustained by a well-regulated process known as thrombopoi‐
esis. In the bone marrow, CD34+ progenitor cells differentiate into polyploid megakaryocytes
(the precursor of platelets). Megakaryocytes lack the expression of CD34, but express several
glycoproteins essential for the platelet function.[23, 24] In general, platelet numbers in blood
range from 150 x 109 to 400 x 109 per liter, and an estimated 1 x 1011 platelets are produced each
day in the adult human. Thrombocytopenia and severe thrombocytopenia characterized as
platelet counts less than 50 x 109 and 10 x 109 per liter, respectively, increase the risk of
spontaneous bleeding and represent a threat for the patient’s life.25 Platelet transfusion has
been widely used to prevent and treat life-threatening thrombocytopenia; however, prepara‐
tion of a unit of concentrated platelets for transfusion requires at least 4–6 units of whole blood,
thereby significantly increasing the risk of blood-borne infections and adverse immunologic
reactions. Furthermore, platelet transfusion refractoriness – lack of adequate post-transfusion
platelet counts – remains a major complication often observed in patients receiving multiple
transfusions. This condition is frequently caused by the development of antibodies specific to
HLA. Currently, platelet transfusion relies on volunteer blood donation; however, the demand
for blood products in particular of platelets often exceeds their availability.[25]
The potential of multipotent progenitor and stem cells in regenerative medicine has been
recognized.[26, 27] Platelet transfusion refractoriness due to the presence of anti-HLA
antibodies constitutes a life-threatening risk for many patients suffering from hematological
disorders, and hence require multiple platelet transfusions. Thus, it would be highly desirable
to produce HLA-deficient platelets to facilitate the management of severe alloimmunized
thrombocytopenic patients. In our studies, we have combined the concept of blood pharming
with RNAi as a strategy to downregulate HLA gene expression. The ultimate goal of this
approach is the large-scale production of platelets in vitro that may be used as an alternative
to the conventional donated blood platelets. In addition, we aim for the production of
genetically modified platelets with the capacity to survive even under platelet transfusion
refractoriness.
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In our studies, CD34+ hematopoietic progenitor cells and induced pluripotent stem cells
(iPSCs) were used to produce HLA-silenced platelets in vitro. CD34+ cells or iPSCs were
transduced with a lentiviral vector encoding for the shRNA sequence targeting β2m which
induces HLA class I silencing. We have demonstrated the feasibility to generate HLA-universal
CD34+ cells and iPSCs which might be used for the differentiation of HLA-silenced cell-
products. In our studies, we have differentiated HLA-silenced megakaryocytes and platelets
from both cell sources. In our previous studies, we have demonstrated the possibility to
generate HLA-silenced platelets with comparable function to blood-derived platelets. How‐
ever, in contrast to blood-derived platelets, in vitro generated HLA-silenced platelets were able
to escape antibody-mediated complement-dependent cytotoxicity as well as cellular-depend‐
ent cytotoxicity. Also, in a platelet transfusion refractoriness mouse model, HLA-silenced
platelets showed the capacity to survive and were even detectable 10 days after transfusion.
[28] The limited availability of CD34+ cells derived from G-CSF mobilized donors is a major
obstacle to the large-scale production of in vitro pharmed platelets. The breakthrough Nobel
Prize–winning research by Yamanaka and colleagues to induce pluripotency in somatic cells
has reshaped the field of stem cell research. Human iPSCs can be used for studying embryo‐
genesis, disease modeling, drug testing, and regenerative medicine.[29] In contrast to CD34+
cells, iPSCs represent an unlimited cell source for the in vitro production of a variety of cell-
based products including platelets. Therefore, we have recently established an efficient
protocol for the differentiation of megakaryocytes and platelets from iPSCs (Figure 2). First,
we have generated an HLA-universal iPSC line. Then, the lentiviral vector containing the
shRNA targeting β2-microglobulin was used to silence HLA expression on iPSCs. A significant
and durable reduction of HLA expression was observed even after passaging. Nevertheless,
the HLA-silenced iPSC line showed comparable expression of pluripotency markers (such as
SSEA-4 and Tra-1-60) as the original HLA class I-expressing iPSC line (Figure 3). The data















Figure 2. Schematic representation of the differentiation of HLA-silenced platelets from iPSCs. A lentiviral vector en‐
coding for an HLA-specific shRNA is used to transduce the iPSCs. Afterward, HLA-silenced iPSCs will be differentiat‐
















































Figure 3. Generation of an HLA-universal iPSC line. (A) iPSCs were adapted to monolayer culture conditions and
transduced with a lentiviral vector encoding for a nonspecific shRNA (shNS) or a β2-microglobulin-specific shRNA to
silence the expression of HLA class I; (B) expression of SSEA4 and Tra-1-60 on nonmodified and shβ2m-expressing
iPSCs; (C) expression of HLA class I of a HLA-silenced shNS-expressing iPSC lines. Cells were stained with an HLA
class I antibody (W6/32) and the expression of HLA was measured by flow cytometry after different number of passag‐
es. Mean fluorescence intensities (MFI) detected on HLA-silenced iPSCs were normalized to the MFI measured on
shNS-expressing iPSCs at the same passage.
In addition, the future application of iPSCs will occur most likely in an allogeneic manner to
facilitate their availability during the time of need and standardization of the protocols. Hence,
the use of HLA-silenced iPSCs may facilitate the application of HLA-mismatched iPSC-
derived cell products. For megakaryocyte differentiation, HLA-silenced iPSCs were cultured
in monolayer in the presence of vascular endothelial growth factor (VEGF) and BMP-4 for
mesoderm induction and afterward in the presence of TPO. During ontogeny, definitive
hematopoietic cells are generated de novo from a specialized subset of endothelium, known
as hemogenic endothelium. Endothelial-to-hematopoietic transition during embryogenesis
provides the first long-term hematopoietic stem and progenitor cells in the embryo.[30] In our
differentiation cultures of iPSCs into megakaryocytes, structures resembling the hemogenic
endothelium were observed (Figure 4). In suspension, megakaryocytes could be detected by
an increase in DNA content higher than 4n and the expression of typical megakaryocytic
markers such as CD41 and CD42a. In addition, the megakaryocytes showed the capability to
build pro-platelets. Moreover, the shRNA-mediated silencing effect was maintained during
the entire differentiation. Importantly, iPSC-derived megakaryocytes and pro-platelets
showed a significant reduction of β2-microglobulin and HLA class I antigens in comparison
to those differentiated from iPSC expressing a nonspecific shRNA (control) (Figure 5).
Differentiation rates of iPSC into megakaryocytes by up to 82% were observed (Figure 6).
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Figure 4. Formation of hemogenic-like endothelium during the differentiation of iPSCs into megakaryocytes. The pho‐




























Figure 5. Differentiation of HLA-universal megakaryocytes from HLA-silenced iPSC. (A) The histogram represents the
flow cytometric analysis of HLA-silenced iPSC-derived megakaryocytes after staining with propidium iodide; (B) light
microscopic and (C) fluorescence microscopic analysis of an iPSC-derived megakaryocyte after staining with 4′,6-Dia‐
midin-2-phenylindol (DAPI, blue); (D) light microscopic analysis of pro-platelets indicated with white arrows; (E) real-
time PCR analysis of β2-microglobulin levels in megakaryocytes derived from iPSCs transduced with a lentiviral
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Figure 6. Phenotypic analysis of HLA-universal megakaryocytes derived from iPSCs. The expression of the megakar‐
yocyte markers CD41 and CD42a was measured by flow cytometry in the cells harvested from the iPSC differentiation
cultures at different time points. The gates in the dotplots indicate megakaryocytes characterized by the double expres‐
sion of CD41 and CD42a.
The complement-dependent cytotoxic (CDC) crossmatch is an informative assay that detects
alloantibodies in pre- and post-transplant patients, which may guide the most appropriate
clinical management of transplant patients.[31] The capacity of in vitro generated HLA-
silenced megakaryocytes and platelets to escape antibody-mediated complement-dependent
cytotoxicity was evaluated in CDC tests. HLA-silenced megakaryocytes incubated with
specific HLA antibodies and complement showed comparable cell lyses rates to the megakar‐
yocytes incubated with nonspecific HLA antibodies. In contrast, significantly higher cell lysis
rates were observed when HLA-expressing megakaryocytes were incubated with specific anti-
HLA antibodies (Figure 7). These data suggest that HLA-universal iPSC-derived megakaryo‐
cytes are protected from anti-HLA antibody-mediated complement-dependent cytotoxicity
and have the potential to survive under refractoriness conditions.
































Figure 7. HLA-silenced megakaryocytes are protected from antibody-mediated complement-dependent cytotoxicity.
HLA-expressing (shNS) or HLA-silenced (shβ2m) iPSC-derived megakaryocytes were incubated with a nonspecific
antibody (NC) or an HLA-specific antibody and complement. Cell lysis was detected by flow cytometric analysis upon
staining with propidium iodide. The bar graph represents means and standard deviations of three independent experi‐
ments. Statistical significance was calculated using Student’s t-test (*p < 0.05, **p < 0.01; ***p < 0.001).
2.5. Generation of HLA-silenced tissues
Due to the high variability of the HLA loci and the shortage of organs and tissues for trans‐
plantation, it is very difficult to find a complete HLA-matched graft for a given recipient. The
number of HLA mismatches between the graft and the recipient are associated with a higher
risk for graft rejection and even morbidity and mortality due to immunosuppression-related
side effects. Thus, it would be desirable to engineer the grafts in order to decrease their
immunogenicity by silencing HLA expression. Worldwide, the demand for organs and tissues
for transplantation is very high and it is not possible to satisfy all needs. This discrepancy is
even accentuated in the Middle East and countries in the East such as India and China.
According to the World Health Organization (WHO), there are over 10 million people in the
world who are blind in one or both eyes due to corneal injury or disease and up to 45 million
people could benefit from corneal transplants. However, according to data from eye banks and
health agencies, less than 150,000 corneal transplants are done annually worldwide due to the
shortage of human cadaver corneas. Furthermore, during the first five years after penetrating
keratoplasty, rejection is responsible for 28–35% of total corneal graft loss. High risk-corneal
recipients even showed increased rejection rates (30–56%).[32, 33]
The cornea presents a simple anatomical structure, in which the endothelium is easily
accessible to the shRNA-encoding viral vector containing supernatant (Figure 8). The integrity
of the endothelial cell layer is crucial for the transparency of the cornea and it is the major
target for rejection. Therefore, silencing HLA expression on the corneal endothelium may
improve cornea survival in high-risk patients after allogeneic keratoplasty.
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Figure 8. Anatomy of the cornea. Optical coherence tomography of a mouse cornea showing the three main layers.
We have silenced HLA expression in human and mice corneas. The tissue was transduced for
8 h with the lentiviral vector encoding for the MHC-specific shRNAs as described above. We
were able to silence the MHC expression on the cornea endothelium, which is the major target
during graft rejection. In this study, we demonstrated the feasibility to generate HLA universal
tissues in their original 3D structure (Figure 9). Silencing HLA expression on tissues is expected
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Figure 9. Generation of MHC-silenced corneas. A mouse cornea was explanted and transduced with a lentiviral vector
encoding the shβ2m to cause a downregulation of MHC class I antigens and the expression of green fluorescence pro‐
tein (GFP) sequences. (A) Light microscopic and (B) fluorescence microscopic analyses of a transduced mouse cornea.
2.6. Conclusion
Recently, gene regulation or editing strategies have emerged as powerful tools to improve the
design and efficacy of personalized cell-based therapies. In the field of histocompatibility and
transplantation, RNAi seems to be a favorite approach to reduce the immunogenicity of
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allogeneic and in vitro generated cells and tissues. The lentiviral vector-mediated delivery of
shRNAs targeting HLA transcripts prevents the activation of cellular and humoral allogeneic
immune responses that cause the rejection of the foreign cells. However, this RNAi-based
strategy permits the residual expression of HLA class I antigens which are crucial to inhibit
NK cell cytotoxicity. With the establishment of iPSCs, the concept of cell pharming came one
step closer to reality as iPSCs may serve as unlimited cell sources for different cell products
such as platelets. The combination of RNAi-mediated HLA silencing and the capacity to
generate platelets in vitro may represent a novel therapeutic approach for the management of
alloimmunized thrombocytopenic patients with an increased risk to develop refractoriness to
platelet transfusion. Furthermore, our results also indicate the feasibility to reduce MHC
expression in the 3D original structure of tissues. Abrogating the histocompatibility barrier
between donors and recipients may improve therapeutic efficacy, reduce the adverse events
associated with strong immunosuppressive regimens, and improve transplant patient life’s
quality. In conclusion, RNAi-mediated silencing of HLA expression may open new avenues
in tissue engineering and transplantation.
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